An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda - both leading their respective drug classes in the
The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche
Five-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off a growing number of contenders to the first-line non-small cell lung cancer (NSC
UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement
Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer from the FDA after the US regulator started a priority review of the drug,